Dexadreson 2 mg/ml solution for injection

Valsts: Īrija

Valoda: angļu

Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)

Aktīvā sastāvdaļa:

Dexamethasone sodium phosphate

Pieejams no:

Intervet Ireland Limited

ATĶ kods:

QH02AB02

SNN (starptautisko nepatentēto nosaukumu):

Dexamethasone sodium phosphate

Deva:

2 milligram(s)/millilitre

Zāļu forma:

Solution for injection

Receptes veids:

POM: Prescription Only Medicine as defined in relevant national legislation

Ārstniecības grupa:

Cats, Cattle, Dogs, Horses, Pigs

Ārstniecības joma:

dexamethasone

Ārstēšanas norādes:

Corticosteroid

Autorizācija statuss:

Authorised

Autorizācija datums:

1989-10-01

Produkta apraksts

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Dexadreson 2 mg/ml solution for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE
Dexamethasone
2.0 mg
(as dexamethasone sodium phosphate)
EXCIPIENT
Benzyl alcohol (E1519)
15.6 mg
For the full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
A clear, colourless solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses, cattle, pigs, dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Dexadreson may be used whenever a parenteral
corticosteroid preparation giving a medium duration of activity is
indicated.
It can be used as an anti-inflammatory and anti-allergic agent in
horses,
cattle,
pigs,
dogs and cats and for
the treatment of primary ketosis in cattle.
The product can also be used to induce parturition in cattle.
Dexadreson is suitable for intravenous use in the horse and
is thus of particular benefit in cases needing emergency treatment.
4.3 CONTRAINDICATIONS
Except in emergency situations, do not use in animals suffering from
diabetes mellitus, chronic nephritis, renal disease,
congestive heart failure, osteoporosis and in viral infections during
the viraemic stage.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Use of the product in horses could predispose to laminitis and
therefore, careful observation during treatment is necessary.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_9_
_/_
_0_
_1_
_/_
_2_
_0_